Journal Watch · Cell Reports · 2026

PRKCI-ECT2 copy number gain promotes developmental reprogramming and metastatic competence in lung adenocarcinoma.

Human LUAD analyses support these progenitor programs as clinically relevant features of PRKCI-ECT2 gain.

Nguyen DT, Meneses KM, Zhang C et al.Cell Reports3 min readPharma relevance 40/100

DOI: 10.1016/j.celrep.2026.117697PMID: 42470637Study type: preclinical (animal / model) study

TL;DR

Human LUAD analyses support these progenitor programs as clinically relevant features of PRKCI-ECT2 gain.

Key findings

  • Human LUAD analyses support these progenitor programs as clinically relevant features of PRKCI-ECT2 gain.

Numbers at a glance (from the abstract)

30%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Using a genetically engineered mouse model that recapitulates PRKCI-ECT2 gain in Kras/Trp53-driven LUAD, we show that elevated PKCι-ECT2 signaling rewires tumor trajectory in a cell-of-origin-dependent manner. Alveolar type II cell-derived tumors dedifferentiate into a distal SOX9<sup>high</sup> progenitor-like state associated with aggressive growth and liver metastasis, whereas club cell-derived tumors transition into a foregut SOX2<sup>high</sup> progenitor-like state that supports lineage infidelity and histological transformation.

Full abstract (original)

Background: Lung adenocarcinoma (LUAD) shows extensive lineage plasticity and early metastatic dissemination, but the oncogenic events that actively drive these processes remain poorly defined. Here, we identify coordinated PRKCI and ECT2 copy number gain, present in approximately 30% of human LUADs, as a driver of developmental reprogramming and metastasis.

What they did: Using a genetically engineered mouse model that recapitulates PRKCI-ECT2 gain in Kras/Trp53-driven LUAD, we show that elevated PKCι-ECT2 signaling rewires tumor trajectory in a cell-of-origin-dependent manner. Alveolar type II cell-derived tumors dedifferentiate into a distal SOX9<sup>high</sup> progenitor-like state associated with aggressive growth and liver metastasis, whereas club cell-derived tumors transition into a foregut SOX2<sup>high</sup> progenitor-like state that supports lineage infidelity and histological transformation.

Results & conclusions: Human LUAD analyses support these progenitor programs as clinically relevant features of PRKCI-ECT2 gain.

Abstract © the authors / Cell Reports (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.celrep.2026.117697 · PubMed 42470637.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Cell Reports study find?

Human LUAD analyses support these progenitor programs as clinically relevant features of PRKCI-ECT2 gain.

What type of study is this?

It is a preclinical (animal / model) study, published in Cell Reports in 2026. Using a genetically engineered mouse model that recapitulates PRKCI-ECT2 gain in Kras/Trp53-driven LUAD, we show that elevated PKCι-ECT2 signaling rewires tumor trajectory in a cell-of-origin-dependent manner.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.celrep.2026.117697. PubMed ID: 42470637. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Nguyen DT, Meneses KM, Zhang C et al.. PRKCI-ECT2 copy number gain promotes developmental reprogramming and metastatic competence in lung adenocarcinoma.. Cell Reports (2026). DOI: 10.1016/j.celrep.2026.117697.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/prkci-ect2-copy-number-gain-promotes-developmental-reprogramming-and-met-117697/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides